The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness In VivoMasanori Niimi, Kathryn J. Wood, Thomas C. Pearson et al.|The Journal of Immunology|1998Cited by 79
Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model FrameworkWeijia Wang, Steve D’Amato, Edward Li et al.|JCO Oncology Practice|2021Cited by 20
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness AnalysisEdward Li, Gary H. Lyman, Dylan Mezzio et al.|JCO Oncology Practice|2021Cited by 19
G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping reviewKim Campbell, Edward Li, Nidhi Chadha et al.|Expert Review of Hematology|2022Cited by 14
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Weijia Wang, Kim Campbell et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 11